The post Here’s How Much Medline’s Founding Family Is Worth, Per Pending IPO appeared on BitcoinEthereumNews.com. Medline’s founding family (from left to right): Jim Abrams, Charlie Mills and Andy Mills. Jeff Sciortino for Forbes The Mills family cashed out a majority stake in the family’s medical supplies firm to private equity in 2021. But the coming $50 billion IPO shows that even what they continue to hold is worth a fortune. Combined, Forbes estimates they’re worth $20 billion. Medical-supplies giant Medline’s IPO is set to be this winter’s blockbuster–worth up to $55 billion. Documents for it also reveal for the first time the remaining stake of the Mills family, who founded the company in 1910 and ran it for generations. In 2021, the family sold a majority stake in the private company to private equity for $30 billion. A new securities filing shows that the Mills family’s stake is worth $6 billion to $7 billion, by Forbes estimates based on the disclosed shareholdings of Mozart HoldCo and an expected share price of $26-to-$30 per share. Combined with an estimated pretax stake of $22 billion from the earlier stake sale, that would give the Mills family–including Charlie Mills, the company’s former CEO; Andy Mills, his cousin and former president; and Jim Abrams, Andy’s brother-in-law and the former chief operating officer–a combined net worth of $20 billion by Forbes estimates. That makes them worth 18 times the $1.1 billion that Forbes calculated they were worth in 2014. The family set up a family office called Council Ring Capital following the 2021 sale, and the trio began stepping back from operations in 2023. Medline did not immediately respond to an email seeking comment. Medline’s roots go back to 1910 when A.L. Mills–the great-grandfather of Charlie Mills–moved from small town Arkansas to Illinois. He sold handmade butcher’s aprons to workers in the city’s vast meatpacking district. After a nun who… The post Here’s How Much Medline’s Founding Family Is Worth, Per Pending IPO appeared on BitcoinEthereumNews.com. Medline’s founding family (from left to right): Jim Abrams, Charlie Mills and Andy Mills. Jeff Sciortino for Forbes The Mills family cashed out a majority stake in the family’s medical supplies firm to private equity in 2021. But the coming $50 billion IPO shows that even what they continue to hold is worth a fortune. Combined, Forbes estimates they’re worth $20 billion. Medical-supplies giant Medline’s IPO is set to be this winter’s blockbuster–worth up to $55 billion. Documents for it also reveal for the first time the remaining stake of the Mills family, who founded the company in 1910 and ran it for generations. In 2021, the family sold a majority stake in the private company to private equity for $30 billion. A new securities filing shows that the Mills family’s stake is worth $6 billion to $7 billion, by Forbes estimates based on the disclosed shareholdings of Mozart HoldCo and an expected share price of $26-to-$30 per share. Combined with an estimated pretax stake of $22 billion from the earlier stake sale, that would give the Mills family–including Charlie Mills, the company’s former CEO; Andy Mills, his cousin and former president; and Jim Abrams, Andy’s brother-in-law and the former chief operating officer–a combined net worth of $20 billion by Forbes estimates. That makes them worth 18 times the $1.1 billion that Forbes calculated they were worth in 2014. The family set up a family office called Council Ring Capital following the 2021 sale, and the trio began stepping back from operations in 2023. Medline did not immediately respond to an email seeking comment. Medline’s roots go back to 1910 when A.L. Mills–the great-grandfather of Charlie Mills–moved from small town Arkansas to Illinois. He sold handmade butcher’s aprons to workers in the city’s vast meatpacking district. After a nun who…

Here’s How Much Medline’s Founding Family Is Worth, Per Pending IPO

Medline’s founding family (from left to right): Jim Abrams, Charlie Mills and Andy Mills.

Jeff Sciortino for Forbes

The Mills family cashed out a majority stake in the family’s medical supplies firm to private equity in 2021. But the coming $50 billion IPO shows that even what they continue to hold is worth a fortune. Combined, Forbes estimates they’re worth $20 billion.

Medical-supplies giant Medline’s IPO is set to be this winter’s blockbuster–worth up to $55 billion. Documents for it also reveal for the first time the remaining stake of the Mills family, who founded the company in 1910 and ran it for generations. In 2021, the family sold a majority stake in the private company to private equity for $30 billion.

A new securities filing shows that the Mills family’s stake is worth $6 billion to $7 billion, by Forbes estimates based on the disclosed shareholdings of Mozart HoldCo and an expected share price of $26-to-$30 per share.

Combined with an estimated pretax stake of $22 billion from the earlier stake sale, that would give the Mills family–including Charlie Mills, the company’s former CEO; Andy Mills, his cousin and former president; and Jim Abrams, Andy’s brother-in-law and the former chief operating officer–a combined net worth of $20 billion by Forbes estimates. That makes them worth 18 times the $1.1 billion that Forbes calculated they were worth in 2014. The family set up a family office called Council Ring Capital following the 2021 sale, and the trio began stepping back from operations in 2023.

Medline did not immediately respond to an email seeking comment.

Medline’s roots go back to 1910 when A.L. Mills–the great-grandfather of Charlie Mills–moved from small town Arkansas to Illinois. He sold handmade butcher’s aprons to workers in the city’s vast meatpacking district. After a nun who worked as a seamstress at a local hospital asked Mills if he could make and sell them hospital garments, the medical business was born. Over the subsequent decades, the company invented the first surgeon’s gown with 360-degree coverage, were among the first to commercialize the blue and green fabrics worn in the operating room to cut down on the lights’ glare, and were first to introduce the now ubiquitous pink-and-blue striped blankets for newborns.

Though Medline’s supplies–everything from baby blankets to bandages–are everywhere, the Mills family was largely unknown until Forbes profiled them in 2020 when Covid-19 was at its peak. At the time, its distribution of medical supplies to nursing homes, pharmacies and 45% of hospital systems nationwide was a critical part of the country’s pandemic response.

Then, in June 2021, the family–which had till then owned 100% of the company–sold a majority stake to a consortium of private-equity firms that included Blackstone Group, Carlyle Group and Hellman & Friedman, who beat out other blue-chip bidders. In October 2023, current CEO Jim Boyle took on that role, the first non-family member to hold it.

Private-equity ownership has been good for Medline. The company’s sales reached $25.5 billion in 2024, up 83% from $13.9 billion five years earlier. Meanwhile profits rebounded to $1.2 billion last year, compared with a small loss two years earlier.

MORE FROM FORBES

ForbesThis Robotic Surgery Legend Is Pouring $100 Million Into Next-Gen Medical StartupsForbesThis Haiti-Born Doctor Built A $6 Billion Business Developing Drugs For Depression And Alzheimer’sForbesHow A Tiny Polish Startup Became The Multi-Billion-Dollar Voice Of AIForbesHow Donald Trump Jr’s Fortune Jumped Six-Fold In A YearForbesCompanies Cut Prices For Blockbuster Weight-Loss Drugs

Source: https://www.forbes.com/sites/amyfeldman/2025/12/08/medlines-mills-founding-family-has-6-billion-plus-stake-in-its-upcoming-blockbuster-ipo/

Market Opportunity
Andy Logo
Andy Price(ANDY)
$0.0000808
$0.0000808$0.0000808
0.00%
USD
Andy (ANDY) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

United States Building Permits Change dipped from previous -2.8% to -3.7% in August

United States Building Permits Change dipped from previous -2.8% to -3.7% in August

The post United States Building Permits Change dipped from previous -2.8% to -3.7% in August appeared on BitcoinEthereumNews.com. Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page. If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet. FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted. The author and FXStreet are not registered investment advisors and nothing in this article is intended…
Share
BitcoinEthereumNews2025/09/18 02:20
UK To Deepen Crypto Ties With US, May Adopt More Pro-Crypto Approach: FT

UK To Deepen Crypto Ties With US, May Adopt More Pro-Crypto Approach: FT

The UK is set to expand cooperation with the US on digital assets while exploring a more crypto-friendly approach to boost innovation and attract investment. [...]
Share
Insidebitcoins2025/09/17 23:42
Samsung To Unveil New AI-Connected Living Lineup at CES 2026

Samsung To Unveil New AI-Connected Living Lineup at CES 2026

Company introduces AI-powered appliances designed to deliver smarter living by enhancing fabric care, air conditioning and cleaning Highlighted models include upgraded
Share
AI Journal2025/12/18 09:16